Cargando…

Simvastatin Ameliorates Liver Fibrosis via Mediating Nitric Oxide Synthase in Rats with Non-Alcoholic Steatohepatitis-Related Liver Fibrosis

BACKGROUND: Simvastatin exerts pleiotropic effects on cardiovascular system. However, its effect on non-alcoholic fatty liver disease, especially the liver fibrosis, remains obscure. We aimed to clarify the relationship between simvastatin and liver fibrosis both in vivo and in vitro. METHODS: A Hig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Wei, Zhao, Caiyan, Zhou, Junying, Zhen, Zhen, Wang, Yadong, Shen, Chuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788732/ https://www.ncbi.nlm.nih.gov/pubmed/24098525 http://dx.doi.org/10.1371/journal.pone.0076538

Ejemplares similares

Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase
por: Iwakiri, Yasuko
Publicado: (2015)

The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2020)

P2X7 Receptor in Alcoholic Steatohepatitis and Alcoholic Liver Fibrosis
por: Xia, Guo-Qing, et al.
Publicado: (2022)

Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis
por: Verlinden, Wim, et al.
Publicado: (2020)

Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis
por: Angelini, Giulia, et al.
Publicado: (2023)

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease
por: Gallego-Durán, Rocío, et al.
Publicado: (2016)

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis
por: Ghandian, Sina, et al.
Publicado: (2022)

Liver sphingomyelin synthase 1 deficiency causes steatosis, steatohepatitis, fibrosis, and tumorigenesis: An effect of glucosylceramide accumulation
por: Li, Zhiqiang, et al.
Publicado: (2021)

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
por: Stefano, J.T., et al.
Publicado: (2015)

Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis
por: Tsukahara, Yuko, et al.
Publicado: (2022)

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
por: Lee, Kuei-Chuan, et al.
Publicado: (2023)

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice
por: Xu, Jia, et al.
Publicado: (2022)

Targeting acid ceramidase ameliorates fibrosis in mouse models of non-alcoholic steatohepatitis
por: Yu, Amy, et al.
Publicado: (2022)

Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
por: Daher, Saleh, et al.
Publicado: (2018)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
por: Tacke, Frank, et al.
Publicado: (2021)

Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis
por: Yu, Rui, et al.
Publicado: (2018)

Heparin modulation on hepatic nitric oxide synthase in experimental steatohepatitis
por: HASSANIN, AMAL, et al.
Publicado: (2014)

Association of sarcopenia with liver fibrosis and steatohepatitis in non-alcoholic fatty liver disease: protocol for a systematic review and meta-analysis
por: Wang, Zheng, et al.
Publicado: (2023)

Usefulness of Transient Elastography for Non-Invasive Diagnosis of Liver Fibrosis in Pediatric Non-Alcoholic Steatohepatitis
por: Kwon, Young Dai, et al.
Publicado: (2019)

Evaluation of Liver Biopsy Findings and Comparison with Noninvasive Fibrosis Scores in Patients with Non-Alcoholic Steatohepatitis
por: Biberci Keskin, Elmas, et al.
Publicado: (2019)

Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system
por: Kostrzewski, Tomasz, et al.
Publicado: (2021)

Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States
por: Eeckhoute, Jérôme
Publicado: (2022)

Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis
por: Kram, Michael
Publicado: (2023)

Correlation between Fibroscan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis
por: Al Danaf, Layal, et al.
Publicado: (2022)

Asymmetric Dimethylarginine Limits the Efficacy of Simvastatin Activating Endothelial Nitric Oxide Synthase
por: Hsu, Chiao‐Po, et al.
Publicado: (2016)

Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Cytokeratin 18, Alanine Aminotransferase, Platelets and Triglycerides Predict the Presence of Nonalcoholic Steatohepatitis
por: Cao, Wei, et al.
Publicado: (2013)

Transplantation of chemically-induced liver progenitor cells ameliorates hepatic fibrosis in mice with diet-induced nonalcoholic steatohepatitis
por: Murakami, Shunsuke, et al.
Publicado: (2022)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2020)

Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice
por: Lebeau, Paul F., et al.
Publicado: (2019)

IL-23 signaling is not an important driver of liver inflammation and fibrosis in murine non-alcoholic steatohepatitis models
por: Heredia, Jose E., et al.
Publicado: (2022)

β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats
por: Sánchez-Quevedo, Janet, et al.
Publicado: (2022)

Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis
por: Mendel, Itzhak, et al.
Publicado: (2016)

Retraction: Nitric Oxide Synthase 2 Induction Promotes Right Ventricular Fibrosis
por: Boehm, Mario, et al.
Publicado: (2022)

Simvastatin Re-Couples Dysfunctional Endothelial Nitric Oxide Synthase in Experimental Subarachnoid Hemorrhage
por: Sabri, Mohammed, et al.
Publicado: (2011)

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis
por: Mazo, Daniel FC, et al.
Publicado: (2013)

Nitric oxide augments mesenchymal stem cell ability to repair liver fibrosis
por: Ali, Gibran, et al.
Publicado: (2012)

MicroRNA-29a Suppresses CD36 to Ameliorate High Fat Diet-Induced Steatohepatitis and Liver Fibrosis in Mice
por: Lin, Hung-Yu, et al.
Publicado: (2019)

Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease
por: Martínez–Sánchez, Celia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3pbis4dfo00354hg1rm4h1d52g